Establishment of Synergistic Chemoimmunotherapy for Head and Neck Cancer Using Peritumoral Immature Dendritic Cell Injections and Low-Dose Chemotherapies
The lack of available tumor antigens with strong immunogenicity, human leukocyte antigen restriction, and immunosuppression via regulatory T-cells (Tregs) and myeloid-derived suppressor cells are limitations for dendritic cell (DC)–based immunotherapy in patients with advanced head and neck cancer (...
Main Authors: | Hiroki Ishii, Kazuaki Chikamatsu, Satoshi Igarashi, Hideyuki Takahashi, Kaname Sakamoto, Hiroji Higuchi, Shota Tanaka, Tomokazu Matsuoka, Keisuke Masuyama |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-02-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523317304242 |
Similar Items
-
THE CHEMOIMMUNOTHERAPY BASED ON DENDRITIC CELLS AND CISPLATIN IN EXPERIMENT
by: Gorbach O. I., et al.
Published: (2014-08-01) -
Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives
by: Rafieh Bagherifar, et al.
Published: (2021-04-01) -
Analysis of Helper T Cell Responses to Cry j 1-Derived Peptides in Patients with Nasal Allergy: Candidate for Peptide-Based Immunotherapy of Japanese Cedar Pollinosis
by: Keisuke Masuyama, et al.
Published: (2009-01-01) -
Neoadjuvant chemoimmunotherapy for inoperable ovarian cancer
by: G A Nerodo, et al.
Published: (2018-02-01) -
Current status of sublingual immunotherapy for allergic rhinitis in Japan
by: Keisuke Masuyama, et al.
Published: (2018-07-01)